Tags

Type your tag names separated by a space and hit enter

Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Am J Hypertens. 2007 Dec; 20(12):1305-11.AJ

Abstract

BACKGROUND

Although telmisartan may be more beneficial for glucose metabolism than other angiotensin II receptor blockers (ARBs), it has not been determined whether telmisartan exerts more favorable effects on biological and functional parameters related to endothelial function than other ARBs.

METHODS

A study with a crossover design was conducted in 40 hypertensive patients (61 +/- 10 years old, mean +/- SD) who had previously been treated with ARBs other than telmisartan or valsartan (ie, ARBs were switched to either telmisartan 40 mg/day or valsartan 80 mg/day, administered alternately for 12 weeks each). Blood examinations were conducted, and the mean reactive hyperemia ratio (mRHR) was measured by plethysmography for each treatment regimen.

RESULTS

There were no significant differences in either blood pressure or plasma levels of monocyte chemoattractant protein-1, C-reactive protein, 3-nitrotyrosine, or vascular cell adhesion molecule-1 between the two treatment regimens. The mRHR (2.7 +/- 1.0 v 2.4 +/- 1.0, mean +/- SD) was larger (P < .05), and the plasma levels of asymmetric dimethylarginine (ADMA) (0.45 +/- 0.08 v 0.50 +/- 0.17 micromol/L, mean +/- SD) and the homeostasis model assessment index of insulin resistance (HOMA-IR) (2.3 +/- 1.6 v 2.8 +/- 2.1, mean +/- SD) were lower (P < .05) in telmisartan-treated patients than in valsartan treated patients. The percent change in ADMA, but not in HOMA-IR, correlated significantly with that in the mRHR (beta = -0.33, t value = -2.00, P = .04).

CONCLUSIONS

At doses producing equivalent hypotensive effects, telmisartan apparently had a more favorable effect on functional parameters related to endothelial function than did valsartan. The reduction in plasma ADMA levels may contribute to this more favorable effect of telmisartan.

Authors+Show Affiliations

Second Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18047921

Citation

Tomiyama, Hirofumi, et al. "Effect of Telmisartan On Forearm Postischemic Hyperemia and Serum Asymmetric Dimethylarginine Levels." American Journal of Hypertension, vol. 20, no. 12, 2007, pp. 1305-11.
Tomiyama H, Yamada J, Koji Y, et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens. 2007;20(12):1305-11.
Tomiyama, H., Yamada, J., Koji, Y., Shiina, K., Yoshida, M., & Yamashina, A. (2007). Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. American Journal of Hypertension, 20(12), 1305-11.
Tomiyama H, et al. Effect of Telmisartan On Forearm Postischemic Hyperemia and Serum Asymmetric Dimethylarginine Levels. Am J Hypertens. 2007;20(12):1305-11. PubMed PMID: 18047921.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. AU - Tomiyama,Hirofumi, AU - Yamada,Jiko, AU - Koji,Yutaka, AU - Shiina,Kazuki, AU - Yoshida,Masanobu, AU - Yamashina,Akira, PY - 2007/04/29/received PY - 2007/05/25/revised PY - 2007/07/28/accepted PY - 2007/12/1/pubmed PY - 2008/2/29/medline PY - 2007/12/1/entrez SP - 1305 EP - 11 JF - American journal of hypertension JO - Am J Hypertens VL - 20 IS - 12 N2 - BACKGROUND: Although telmisartan may be more beneficial for glucose metabolism than other angiotensin II receptor blockers (ARBs), it has not been determined whether telmisartan exerts more favorable effects on biological and functional parameters related to endothelial function than other ARBs. METHODS: A study with a crossover design was conducted in 40 hypertensive patients (61 +/- 10 years old, mean +/- SD) who had previously been treated with ARBs other than telmisartan or valsartan (ie, ARBs were switched to either telmisartan 40 mg/day or valsartan 80 mg/day, administered alternately for 12 weeks each). Blood examinations were conducted, and the mean reactive hyperemia ratio (mRHR) was measured by plethysmography for each treatment regimen. RESULTS: There were no significant differences in either blood pressure or plasma levels of monocyte chemoattractant protein-1, C-reactive protein, 3-nitrotyrosine, or vascular cell adhesion molecule-1 between the two treatment regimens. The mRHR (2.7 +/- 1.0 v 2.4 +/- 1.0, mean +/- SD) was larger (P < .05), and the plasma levels of asymmetric dimethylarginine (ADMA) (0.45 +/- 0.08 v 0.50 +/- 0.17 micromol/L, mean +/- SD) and the homeostasis model assessment index of insulin resistance (HOMA-IR) (2.3 +/- 1.6 v 2.8 +/- 2.1, mean +/- SD) were lower (P < .05) in telmisartan-treated patients than in valsartan treated patients. The percent change in ADMA, but not in HOMA-IR, correlated significantly with that in the mRHR (beta = -0.33, t value = -2.00, P = .04). CONCLUSIONS: At doses producing equivalent hypotensive effects, telmisartan apparently had a more favorable effect on functional parameters related to endothelial function than did valsartan. The reduction in plasma ADMA levels may contribute to this more favorable effect of telmisartan. SN - 0895-7061 UR - https://www.unboundmedicine.com/medline/citation/18047921/Effect_of_telmisartan_on_forearm_postischemic_hyperemia_and_serum_asymmetric_dimethylarginine_levels_ L2 - https://academic.oup.com/ajh/article-lookup/doi/10.1016/j.amjhyper.2007.07.013 DB - PRIME DP - Unbound Medicine ER -